重症相关皮质类固醇功能不全(CIRCI)诊断与管理指南(第一部分):美国重症医学会(SCCM)与欧洲重症医学会(ESICM)2017
该指南由SCCM和ESICM的16名国际专家组成的多学科工作组制定,采用GRADE方法,在2008年共识基础上结合2008至2017年更新的系统评价证据,对成人及儿科重症患者CIRCI的诊断和治疗给出推荐。诊断方面,工作组未能就单一可靠诊断试验达成一致,但临床医生可使用促肾上腺皮质激素(250 μg)后60分钟皮质醇变化<9 μg/dL或随机血浆皮质醇<10 μg/dL。治疗方面,建议对液体和中等至大剂量血管加压药无反应的感染性休克患者静脉使用氢化可的松<400 mg/天≥3天(弱推荐);不建议无休克脓毒症成人使用皮质类固醇(弱推荐);建议早期中重度ARDS(PaO2/FiO2<200且起病14天内)静脉使用甲泼尼龙1 mg/kg/天(弱推荐);不建议严重创伤患者使用(弱推荐)。
要点
- 感染性休克对液体和中等至大剂量血管加压药无反应时,建议静脉氢化可的松<400 mg/天、≥3天足量(弱推荐,低质量证据)。
- 无休克的成人脓毒症不建议使用皮质类固醇(弱推荐,中等质量证据)。
- 早期中重度ARDS(PaO2/FiO2<200且起病14天内)建议静脉甲泼尼龙1 mg/kg/天(弱推荐,中等质量证据)。
- 严重创伤患者不建议使用皮质类固醇(弱推荐,低质量证据)。
- CIRCI无单一可靠诊断试验;促肾上腺皮质激素(250 μg)后60分钟皮质醇变化<9 μg/dL或随机血浆皮质醇<10 μg/dL可供临床使用。
适用人群与场景
- 成人及儿科重症患者(指南覆盖范围)。
- 感染性休克:对液体和中等至大剂量血管加压药无反应的患者。
- 脓毒症无休克成人患者。
- 早期中重度急性呼吸窘迫综合征:PaO2/FiO2<200且起病14天内。
- 严重创伤患者。
诊断标准与关键阈值
- 工作组未能就单一可靠诊断CIRCI的试验达成一致。
- 临床医生可使用促肾上腺皮质激素(250 μg)后60分钟皮质醇变化<9 μg/dL(delta cortisol)或随机血浆皮质醇<10 μg/dL。
- 建议不采用血浆游离皮质醇或唾液皮质醇水平替代血浆总皮质醇(弱推荐,极低质量证据)。
处置流程与药物剂量
- 感染性休克对液体和中等至大剂量血管加压药无反应:建议静脉氢化可的松<400 mg/天,≥3天足量给药(弱推荐,低质量证据)。
- 成人脓毒症无休克:不建议使用皮质类固醇(弱推荐,中等质量证据)。
- 早期中重度ARDS(PaO2/FiO2<200且起病14天内):建议静脉甲泼尼龙1 mg/kg/天(弱推荐,中等质量证据)。
- 严重创伤:不建议使用皮质类固醇(弱推荐,低质量证据)。
研究设计与关键结果
- 制定机构:SCCM与ESICM多学科工作组,16名国际专家(重症医学、内分泌学、指南方法学)。
- 方法:基于2008年文件汇总证据及2008至2017年更新的系统评价,采用GRADE方法;推荐强度分为强或弱,证据质量从高到极低;推荐需至少80%工作组成员同意。
- 诊断:无法就单一可靠诊断CIRCI的试验达成一致;促肾上腺皮质激素(250 μg)后60分钟皮质醇变化<9 μg/dL或随机血浆皮质醇<10 μg/dL可供临床医生使用。
- 治疗:感染性休克对液体和中等至大剂量血管加压药无反应者建议静脉氢化可的松<400 mg/天≥3天(弱推荐,低质量证据);无休克脓毒症成人不建议使用(弱推荐,中等质量证据);早期中重度ARDS(PaO2/FiO2<200且起病14天内)建议静脉甲泼尼龙1 mg/kg/天(弱推荐,中等质量证据);严重创伤不建议使用(弱推荐,低质量证据)。
证据类型、等级与局限
- 证据类型:指南(SCCM与ESICM共同制定)。
- 证据分级体系:GRADE,推荐强度分为强或弱,证据质量从高到极低。
- 推荐强度标签:条件推荐(弱推荐),证据质量分别为低、中等、极低。
- 局限:原文未报告局限性
对床旁实践的改变
- 对液体和中等至大剂量血管加压药无反应的感染性休克患者,可考虑静脉氢化可的松<400 mg/天、≥3天足量给药(弱推荐,低质量证据)。
- 成人脓毒症无休克不建议使用皮质类固醇(弱推荐,中等质量证据)。
- 早期中重度ARDS(PaO2/FiO2<200且起病14天内)可考虑静脉甲泼尼龙1 mg/kg/天(弱推荐,中等质量证据)。
- 严重创伤患者不建议使用皮质类固醇(弱推荐,低质量证据)。
- 诊断CIRCI时,临床医生可使用促肾上腺皮质激素(250 μg)后60分钟皮质醇变化<9 μg/dL或随机血浆皮质醇<10 μg/dL;建议不采用血浆游离皮质醇或唾液皮质醇替代血浆总皮质醇(弱推荐,极低质量证据)。
指南或共识出处
- Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.
- 发布机构:Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM)
- 年份:2017
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To update the 2008 consensus statements for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in adult and pediatric patients.
PARTICIPANTS: A multispecialty task force of 16 international experts in critical care medicine, endocrinology, and guideline methods, all of them members of the Society of Critical Care Medicine and/or the European Society of Intensive Care Medicine.
DESIGN/METHODS: The recommendations were based on the summarized evidence from the 2008 document in addition to more recent findings from an updated systematic review of relevant studies from 2008 to 2017 and were formulated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. The strength of each recommendation was classified as strong or conditional, and the quality of evidence was rated from high to very low based on factors including the individual study design, the risk of bias, the consistency of the results, and the directness and precision of the evidence. Recommendation approval required the agreement of at least 80% of the task force members.
RESULTS: The task force was unable to reach agreement on a single test that can reliably diagnose CIRCI, although delta cortisol (change in baseline cortisol at 60 min of < 9 μg/dL) after cosyntropin (250 μg) administration and a random plasma cortisol of < 10 μg/dL may be used by clinicians. We suggest against using plasma-free cortisol or salivary cortisol level over plasma total cortisol (conditional, very low quality of evidence). For treatment of specific conditions, we suggest using IV hydrocortisone < 400 mg/day for ≥ 3 days at full dose in patients with septic shock that is not responsive to fluid and moderate- to high-dose vasopressor therapy (conditional, low quality of evidence). We suggest not using corticosteroids in adult patients with sepsis without shock (conditional recommendation, moderate quality of evidence). We suggest the use of IV methylprednisolone 1 mg/kg/day in patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and within 14 days of onset) (conditional, moderate quality of evidence). Corticosteroids are not suggested for patients with major trauma (conditional, low quality of evidence).
CONCLUSIONS: Evidence-based recommendations for the use of corticosteroids in critically ill patients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma have been developed by a multispecialty task force.
参考来源
- Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2017. PMID: 28938253. doi:10.1097/CCM.0000000000002737
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。